Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)
This study (n=691) aimed to validate the Ego-Dissolution Inventory (EDI) as well as to investigate the specificity of the relationship between psychedelics and ego-dissolution. The results demonstrate the psychometric structure, internal consistency, and construct validity of the EDI. It was confirmed that ego-dissolution is specific for experiences induced by psychedelic drugs and not by alcohol or cocaine.
Authors
- Robin Carhart-Harris
- David Nutt
- John Evans
Published
Abstract
Aims
The experience of a compromised sense of “self”, termed ego-dissolution, is a key feature of the psychedelic experience. This study aimed to validate the Ego-Dissolution Inventory (EDI), a new 8-item self-report scale designed to measure ego-dissolution. Additionally, we aimed to investigate the specificity of the relationship between psychedelics and ego-dissolution.
Method
Sixteen items relating to altered ego-consciousness were included in an internet questionnaire; eight relating to the experience of ego-dissolution (comprising the EDI), and eight relating to the antithetical experience of increased self-assuredness, termed ego-inflation. Items were rated using a visual analog scale. Participants answered the questionnaire for experiences with classical psychedelic drugs, cocaine and/or alcohol. They also answered the seven questions from the Mystical Experiences Questionnaire (MEQ) relating to the experience of unity with one’s surroundings.
Results
Six hundred and ninety-one participants completed the questionnaire, providing data for 1828 drug experiences (1043 psychedelics, 377 cocaine, 408 alcohol). Exploratory factor analysis demonstrated that the eight EDI items loaded exclusively onto a single common factor, which was orthogonal to a second factor comprised of the items relating to ego-inflation (rho = −0.110), demonstrating discriminant validity. The EDI correlated strongly with the MEQ-derived measure of unitive experience (rho = 0.735), demonstrating convergent validity. EDI internal consistency was excellent (Cronbach’s alpha 0.93). Three analyses confirmed the specificity of ego-dissolution for experiences occasioned by psychedelic drugs. Firstly, EDI score correlated with drug-dose for psychedelic drugs (rho = 0.371), but not for cocaine (rho = 0.115) or alcohol (rho = −0.055). Secondly, the linear regression line relating the subjective intensity of the experience to ego-dissolution was significantly steeper for psychedelics (unstandardized regression coefficient = 0.701) compared with cocaine (0.135) or alcohol (0.144). Ego-inflation, by contrast, was specifically associated with cocaine experiences. Finally, a binary Support Vector Machine classifier identified experiences occasioned by psychedelic drugs vs. cocaine or alcohol with over 85% accuracy using ratings of ego-dissolution and ego-inflation alone.
Conclusion
Our results demonstrate the psychometric structure, internal consistency and construct validity of the EDI. Moreover, we demonstrate the close relationship between ego-dissolution and the psychedelic experience. The EDI will facilitate the study of the neuronal correlates of ego-dissolution, which is relevant for psychedelic-assisted psychotherapy and our understanding of psychosis.
Research Summary of 'Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)'
Introduction
Distortions in the subjective sense of self, often referred to as ego-dissolution, are a central feature of the psychedelic experience. Previous work has reported reductions in self-referential awareness with classical 5-HT2A agonists such as psilocybin, LSD and DMT, and related phenomena have been described in other altered states (for example, during ketamine or nitrous oxide use). Existing questionnaires of altered states capture a range of depersonalisation and visionary experiences, but the authors identify a gap: there was no brief, validated, uni-dimensional self-report measure that directly operationalises ego-dissolution as a construct, which limits psychometric, neurobiological and clinical research into this specific aspect of psychedelic states. Nour and colleagues therefore developed the Ego-Dissolution Inventory (EDI), an 8-item self-report scale intended to measure ego-dissolution succinctly. Using an anonymous internet survey, the study aimed to validate the EDI psychometrically (factor structure, internal consistency, convergent and discriminant validity), to test whether ego-dissolution is specifically associated with psychedelic drugs versus cocaine or alcohol, and to explore relationships with dose, subjective intensity and changes in well-being. A secondary hypothesis was that stimulant drugs such as cocaine would be associated with an opposite phenomenon—termed ego-inflation—rather than ego-dissolution.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Topic
- Authors
- APA Citation
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). Frontiers in Human Neuroscience, 10. https://doi.org/10.3389/fnhum.2016.00269
References (31)
Papers cited by this study that are also in Blossom
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Friston, K. J. · Brain (2010)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Murphy, K., Leech, R. et al. · Biological Psychiatry (2015)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Hasler, F., Grimberg, U., Benz, M. A. et al. · Psychopharmacology (2004)
Show all 31 referencesShow fewer
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Speth, J., Speth, C., Kaelen, M. et al. · Journal of Psychopharmacology (2016)
Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Trichter, S., Klimo, J., Krippner, S. · Journal of Psychoactive Drugs (2009)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Wittmann, M., Carter, O., Hasler, F. et al. · Journal of Psychopharmacology (2007)
Cited By (161)
Papers in Blossom that reference this study
Mallaroni, P., Singleton, P., Mason, N. L. et al. · Molecular Psychiatry (2026)
Lewis-Healey, E., Pallavicini, C., Cavanna, F. et al. · Journal of Cognitive Neuroscience (2025)
Marsden, J., Kelleher, M., Dunbar, F. et al. · Addiction (2025)
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Beatriz, M., Millón, B., Noguera, L. et al. · Neuropsychopharmacology (2025)
Roseby, W., Kettner, H., Roseman, L. et al. · Frontiers in Psychology (2025)
Reckweg, J. T., Mason, N. L., Theunissen, E. L. et al. · Frontiers in Psychology (2025)
Kugel, J., Laukkonen, R., Yaden, D. B. et al. · Neuroscience and Biobehavioral Reviews (2025)
Fink-Jensen, A., Jensen, M. E., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2025)
Irrmischer, M., Puxty, D. J., Deijen, J. B. et al. · Psychopharmacology (2025)
Show all 161 papersShow fewer
Ruban, A., Magnuski, M., Hobot, J. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025)
Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)
Olami, A., Peled-Avron, L. · Scientific Reports (2024)
Erritzoe, D., Barba, T., Greenway, K. T. et al. · EClinicalMedicine (2024)
Calder, A. E., Rausch, B., Liechti, M. E. et al. · Journal of Psychopharmacology (2024)
Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)
Kettner, H., Roseman, L., Gazzaley, A. et al. · The American Journal of Geriatric Psychiatry (2024)
Rucker, J., Roberts, C. A., Seynaeve, M. et al. · Journal of Psychopharmacology (2024)
Peill, J. M., Marguilho, M., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)
Cherniak, A. D., Mikulincer, M., Brulin, J. G. et al. · Journal of Psychedelic Studies (2024)
Tap, S. C. · Addiction Biology (2024)
Orłowski, P., Hobot, J., Ruban, A. et al. · Psychophysiology (2024)
Erritzoe, D., Barba, T., Spriggs, M. J. et al. · Journal of Psychopharmacology (2024)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)
Acevedo, E. C., Uhler, S., White, K. et al. · Journal of Psychoactive Drugs (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Psychoactive Drugs (2024)
De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)
Siva, J. B., Barba, T., Kettner, H. et al. · Journal of Psychopharmacology (2024)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · NeuroImage (2024)
David, J., Bouso, J. C., Kohek, M. et al. · Frontiers in Psychiatry (2023)
Harduf, A., Panishev, G., Harel, E. V. et al. · Scientific Reports (2023)
Kvam, T-M., Uthaug, M. V., Andersen, K. A. A. et al. · Frontiers in Psychiatry (2023)
Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Wall, M. B., Harding, R., Zafar, R. et al. · Molecular Psychiatry (2023)
Bouso, J. C., Révész, D., Ona, G. et al. · Scientific Reports (2023)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)
Metastasio, A., Mignogna, S., Paci, R. et al. · Drug Science Policy and Law (2023)
Lawrence, D. W., Timmermann, C. · Journal of Psychoactive Drugs (2023)
Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)
Bloesch, E. K., Davis, A. K., Domoff, S. E. et al. · Psyarxiv (2023)
Azmoodeh, K., Thomas, E., Kamboj, S. K. · Experimental and Clinical Psychopharmacology (2023)
Newton, K., Moreton, S. G. · Ecopsychology (2023)
Girn, M., Rosas, F. E., Daws, R. E. et al. · Trends in Cognitive Sciences (2023)
Kangaslampi, S. · Journal of Psychedelic Studies (2023)
Weiss, B., Sleep, C., Miller, J. D. et al. · Journal of Personality Disorders (2023)
Simonsson, A., Simonsson, O., Chambers, R. et al. · Mindfulness (2023)
Kaup, K. K., Vasser, M., Tulver, K. et al. · Frontiers in Psychiatry (2023)
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Peterson, A., Largent, E. A., Sisti, D. et al. · AJOB Neuroscience (2022)
Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)
Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. et al. · Frontiers in Psychiatry (2022)
Guss, J. · Psychoanalytic Dialogues (2022)
Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)
Cruzat, J., Perl, Y. S., Escrichs, A. et al. · Network Neuroscience (2022)
Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)
Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Barba, T., Buehler, S., Kettner, H. et al. · BJPsych Open (2022)
Girn, M., Roseman, L., Bernhardt, B. et al. · NeuroImage (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Hipólito, I., Mago, J., Rosas, F. E. et al. · Psyarxiv (2022)
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Amada, N., Shane, J. · Journal of Humanistic Psychology (2022)
Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Scientific Reports (2022)
Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)
Lawrence, D. W., Carhart-Harris, R. L., Griffiths, R. R. et al. · Research Square (2022)
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Tagliazucchi, E. · Frontiers in Pharmacology (2022)
Gandy, S. · Journal of Psychedelic Studies (2022)
Timmermann, C., Watts, R., Dupuis, D. · Transcultural Psychiatry (2022)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Villiger, D. · Frontiers in Psychiatry (2022)
Family, N., Hendricks, P. S., Williams, L. T. J. et al. · Journal of Psychopharmacology (2022)
Argento, E., Socias, M. E., Hayashi, K. et al. · International Journal of Drug Policy (2022)
Ramaekers, J. G. · Psychopharmacology (2022)
Simonsson, O., Goldberg, S. B. · Journal of Psychoactive Drugs (2022)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · MedRvix (2021)
Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)
Whitfield, H. J. · Frontiers in Psychiatry (2021)
Reckweg, J., Mason, N. L., van Leeuwen, C. et al. · Frontiers in Pharmacology (2021)
Strumila, R., Guillaume, S. · Pharmaceuticals (2021)
Kuc, J., Kettner, H., Rosas, F. E. et al. · Psychopharmacology (2021)
Johnstad, P. G. · Journal of Psychedelic Studies (2021)
van Oorsouw, K., Uthaug, M. V., Mason, N. L. et al. · Journal of Psychedelic Studies (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Zamani, A., Carhart-Harris, R. L., Christoff, K. · Neuropsychopharmacology (2021)
Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J. et al. · Frontiers in Psychiatry (2021)
Hübner, S., Haijen, E. C. H. M., Kaelen, M. et al. · Journal of Medical Internet Research (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Ballentine, G., Friedman, S. F., Bzdok, D. · Science Advances (2021)
Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)
Gearin, A. K., Devenot, N. · International Journal of Cultural Studies (2021)
Lewis-Healey, E., Laukkonen, R., Van Elk, M. · Psyarxiv (2021)
Roseman, L., Ron, Y., Saca, A. et al. · Frontiers in Pharmacology (2021)
Yaden, D. B., Johnson, M. W., Griffiths, R. R. et al. · International Journal of Neuropsychopharmacology (2021)
González, D., Cantillo, J., Perez, I. et al. · Frontiers in Pharmacology (2021)
Hartogsohn, I. · Frontiers in Pharmacology (2021)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Sanz, C., Pallavicini, C., Carrillo, F. et al. · Consciousness and Cognition (2021)
Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Van Mulukom, V., Patterson, R. E., Van Elk, M. · Psychopharmacology (2020)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Association for Computing Machinery (2020)
Madsen, M. K., Fisher, P. M., Stenbæk, D. S. et al. · European Neuropsychopharmacology (2020)
Deane, G. · Philosophy and the Mind Sciences (2020)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Bienemann, B., Ruschel, N. S., Campos, M. L. et al. · PLOS ONE (2020)
Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)
Forstmann, M., Yudkin, D. A., Prosser, A. M. B. et al. · PNAS (2020)
Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)
Uthaug, M. V., Lancelotta, R., Szabo, A. et al. · Psychopharmacology (2019)
Moreton, S. G., Szalla, L., Menzies, R. E. et al. · Psychopharmacology (2019)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychopharmacology (2019)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychology of Consciousness Theory Research and Practice (2019)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Carhart-Harris, R. L. · Current Opinion in Psychiatry (2019)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Hendricks, P. S. · International Review of Psychiatry (2018)
Bayne, T., Carter, O. · Neuroscience of Consciousness (2018)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Lyons, T., Carhart-Harris, R. L. · Journal of Psychopharmacology (2018)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Letheby, C., Gerrans, P. · Neuroscience of Consciousness (2017)
Millière, R. · Frontiers in Human Neuroscience (2017)
Nour, M. R., Evans, J., Carhart-Harris, R. L. · Journal of Psychoactive Drugs (2017)
Kaelen, M. · Imperial College London (2017)
Nour, M. R., Carhart-Harris, R. L. · British Journal of Psychiatry (2017)
Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)
Bryson, A., Carter, O., Norman, T. et al. · International Journal of Neuropsychopharmacology (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.